SANDOZ/CIBA MERGER UNITES TWO BROAD BIOTECHNOLOGY PORTFOLIOS WITH PARTICULAR STRENGTH IN GENE THERAPY; BIOTECH STRATEGIES OF TWO COMPANIES HAVE DIFFERED
Executive Summary
The Sandoz/Ciba merger will combine two companies that share a common interest in investment in outside research firms but have different strategies in shaping their biotechnology agreements.